Vascular Endothelial Factor Gene Polymorphism in Preeclampsia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

290 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-31

Study Completion Date

2018-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, the investigators assessed one of the released protein factors during the pathophysiology of preeclampsia. They evaluated vascular endothelial growth factor gene mutation which affects the angiogenesis in case of inadequate placentation and its association with Doppler changes in the pulsatility index of the umbilical artery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Placental Protein 13 Serum Endoglin and Uterine Doppler Indeces as Predictors of Pre-eclampsia

NCT02350036

Preeclampsia

COMPLETED

Combined 3D Power Doppler Placental Volume and Vascular Flow Indices In the First Trimester of Pregnancy as Predictors Of Preeclampsia?.

NCT03399006

Preeclampsia

UNKNOWN

Prediction of Outcome in Severe Preeclampsia

NCT03871764

Leiden Factor V Deficiency,Preeclampsia Doppler Examination Palental Pathology

COMPLETED

Comparison Between Uterine Artery Doppler and Placental Vascular Indices in Prediction of Preeclampsia

NCT03838887

Pre-Eclampsia

UNKNOWN

Certain Maternal Antibodies in Relation to Doppler in Hypertension With Pregnancy

NCT03214393

Pre-Eclampsia

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Preeclampsia is a syndrome characterized by occurrence of hypertension and proteinuria after 20 weeks of gestation. The pathophysiology of preeclampsia involves abnormalities in the development of placental vasculature early in pregnancy may result in relative placental under perfusion/hypoxia/ischemia, which then leads to release of factors into the maternal circulation that alter maternal endothelial function and cause hypertension and other manifestations of disease .Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates vasculogenesis and angiogenesis. It is part of the system that restores the oxygen supply to tissues when blood circulation is inadequate. Human VEGF gene is located on chromosome 6 and consists of 8 exons with alternate splicing, forming a family of proteins. There are several common single nucleotide polymorphisms (SNPs) in the VEGF gene, which could alter gene expression and protein production, and alter the risk of developing diseases characterized by deranged angiogenesis including preeclampsia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preeclampsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

normotensive pregnant women more than 20 weeks gestation.

One hundred and forty-five pregnant women after 20 weeks with normal blood pressure were evaluated for VEGF gene mutation.

PCR

Intervention Type DIAGNOSTIC_TEST

Polymerase chain reaction was used to diagnose gene polymorphism.

Pregnant women after 20 weeks with preeclampsia.

One hundred and forty-five pregnant women after 20 weeks with preeclampsia were evaluated for VEGF gene mutation by using PCR and Pulsitality index of umbilical artery by doppler velocimetry.

PCR

Intervention Type DIAGNOSTIC_TEST

Polymerase chain reaction was used to diagnose gene polymorphism.

Doppler ultrasound

Intervention Type DEVICE

Doppler ultrasound was used to assess the pulsatility index of the umbilical artery .

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PCR

Polymerase chain reaction was used to diagnose gene polymorphism.

Intervention Type DIAGNOSTIC_TEST

Doppler ultrasound

Doppler ultrasound was used to assess the pulsatility index of the umbilical artery .

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

More than 20 weeks gestation. Preeclamptic patients

Exclusion Criteria

association with chronic disease (cardiac, hepatic, renal) and if the patient was known to have chronic hypertension.

association with auto-immune disease.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No